Neuroendocrine tumors are well known for their over-expression of somatostatin receptors (SST), especially of SST2A, but also SST5, which represent the molecular basis of different SST-based diagnostic and treatment modalities. The gene discussed is SST; the disease is neuroendocrine neoplasm.